Chinese companies announce major investments to combat MNC players

By PharmaCompass

2018-12-13

Impressions: 113 Article

In China, home-grown drugmakers are busy stepping up their game as they find multinational drug players producing more drugs in their home turf after the country eased rules to allow data from trials that were not done in China.

In August, China put out a target list of 48 treatments that are approved abroad, including some of the industry’s biggest names, in the hope of getting drugmakers to apply for Chinese approval based on foreign trial data. The list includes drugs like Roche and Chugai’s ALK cancer drug Alecensa , psoriasis therapies Taltz by Eli Lilly, Cosentyx from Novartis and GlaxoSmithKline’s shingles vaccine Shingrix.

Last week, there was news that a Chinese maker of heparin, APIs and some finished drugs — Changzhou Qianhong Bio-pharma — is launching the second phase of its manufacturing plant, investing nearly US$ 150 million as it moves into producing innovative biologic drugs for the Chinese market. The company has begun construction of the US$ 145 million (¥1 billion) project in the Changzhou National Hi-Tech District. It says when complete, the facility will add 200 million tablets and 60 million injections to its production, as well as making molecular diagnosis reagents.

Similarly, STA Pharmaceutical, a subsidiary of Wuxi AppTec, plans to add one API plant every year. It has planned on a major expansion in Changzhou, China. It will also look for opportunities to enter new geographic regions.

The PharmaCompass Newsletter – Sign Up, Stay Ahead

Feedback, help us to improve. Click here

Image Credit : #Phisper Infographic by SCORR MARKETING & PharmaCompass is licensed under CC BY 2.0

“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”

NEWS

DRUGS & DEVELOPMENTS

MARKET INTEL by PharmaCompass